B
CGEM icon

Braidwell’s Cullinan Oncology CGEM Stock Holding History

Braidwell’s Portfolio CGEM Stock Details CGEM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-980,773
Closed -$7.42M – 59
2025
Q1 		$7.42M Sell
980,773
-195,400
-17% -$1.87M 0.26% 53
2024
Q4 		$14.3M Hold
1,176,173
– – 0.42% 58
2024
Q3 		$19.7M Buy
1,176,173
+1,000,000
+568% +$17.7M 0.56% 50
2024
Q2 		$3.07M Sell
176,173
-1,064,692
-86% -$22.7M 0.1% 72
2024
Q1 		$21.1M Hold
1,240,865
– – 0.68% 46
2023
Q4 		$12.6M Sell
1,240,865
-668,000
-35% -$5.92M 0.46% 53
2023
Q3 		$17.3M Hold
1,908,865
– – 0.55% 61
2023
Q2 		$20.5M Buy
+1,908,865
New +$20.3M 0.67% 53

Other funds holding CGEM

MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

Braidwell's CGEM Position: Q2 2025 in Review

Braidwell sold out of Cullinan Oncology (CGEM) in Q2 2025, closing a stake of 980,773 shares — an estimated $7.42M sold.

Braidwell first reported a position in CGEM in Q2 2023 and held it in 8 quarters. The position peaked at $21.1M in Q1 2024. 143 funds tracked by Wall St. Rank hold CGEM as of Q2 2025.

  • Braidwell reported no remaining Cullinan Oncology position as of Q2 2025 after selling out during the quarter.
  • Braidwell sold 980,773 Cullinan Oncology shares in Q2 2025, an estimated $7.42M.
  • Braidwell first reported a position in Cullinan Oncology in Q2 2023 and held it in 8 quarters.
  • Braidwell's Cullinan Oncology position peaked at $21.1M in Q1 2024.
  • 143 funds tracked by Wall St. Rank held Cullinan Oncology as of Q2 2025.

Based on Braidwell's 13F filing for Q2 2025, filed 14 Aug 2025.